A Phase I, Open Label, Study of 3,4-Methylenedioxymethamphetamine (MDMA) Tolerability and Pharmacokinetics in Subjects With Moderate Hepatic Impairment Compared to Matched Control Subjects With Normal Hepatic Function

The goal of this clinical trial to learn how MDMA is processed in people with abnormal liver function.
The main questions it aims to answer are:
Do people with abnormal liver function experience greater absorption of MDMA? Does the dose of MDMA need to be adjusted in people with abnormal liver function?
Researchers will compare people with abnormal liver function to people with normal liver function.
Participants will receive a single dose of MDMA then undergo periodic vitals measurements. They will remain at the study site for two more days undergoing more vitals measurements and having subjective effects and adverse events measured.

Start Date29 Mar 2026

Sponsor / Collaborator

Lykos Therapeutics, Inc.

NCT04454684

/ WithdrawnPhase 2

An Open-Label, Multi-Site Phase 2 Study of the Safety and Feasibility of MDMA-Assisted Psychotherapy for Eating Disorders

The goal of this clinical trial is to learn if MDMA-assisted therapy and caregiver involvement are safe and effective in treating female participants with eating disorders.
The main question it aims to answer is: Does MDMA-assisted therapy reduce eating disorder symptoms?
Participants will undergo two non-drug preparatory therapy sessions and their caregiver will undergo one non-drug preparatory therapy session. Participants will undergo three sessions of MDMA-assisted therapy followed by non-drug integrative therapy sessions alone as well as together with their caregiver.

Start Date01 Feb 2026

Sponsor / Collaborator

Lykos Therapeutics, Inc.

NCT06353282

/ WithdrawnPhase 2IIT

3, 4-methylenedioxymethamphetamine (MDMA) for Treatment-resistant Post-traumatic Stress Disorder (PTSD) in Adolescents

The primary objective of this study is to determine the safety and feasibility of 3,4-methylenedioxymethamphetamine (MDMA) -assisted psychotherapy to treat resistant post-traumatic stress disorder (PTSD). The secondary objectives are the exploration of effectiveness for treatment-resistant PTSD, symptoms of depression, and anxiety symptoms.

Start Date01 Jul 2025

Sponsor / Collaborator

University of California, Los Angeles

100 Clinical Results associated with Methylenedioxymetamfetamine

100 Translational Medicine associated with Methylenedioxymetamfetamine

100 Patents (Medical) associated with Methylenedioxymetamfetamine

9,599

Literatures (Medical) associated with Methylenedioxymetamfetamine

31 Dec 2025·European Journal of Psychotraumatology

Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder

Article

Author: Zeifman, Richard J. ; Mitchell, Jennifer M. ; Agin-Liebes, Gabrielle

Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcohol use disorder, and substance use disorders. A well-powered phase 3 randomized, placebo-controlled trial has shown that MDMA-assisted therapy (MDMA-AT) may be an effective treatment for severe PTSD. However, the psychological mechanisms driving the therapeutic effects of MDMA-AT remain unclear. One potential mechanism is self-compassion, which is commonly conceptualized as a balance between compassionate self-responding (CS) - encompassing self-kindness, common humanity, and mindfulness - and uncompassionate self-responding (UCS) - encompassing self-judgment, isolation, and over-identification.Objective: This secondary analysis aimed to explore whether MDMA-AT enhances aspects of self-compassion and if changes in self-compassion mediate the therapy's effectiveness in reducing PTSD severity, depressive, and alcohol and substance use symptoms.Method: Eighty-two adults diagnosed with severe PTSD participated in a double-blind trial comparing three sessions of either MDMA-AT or placebo combined with therapy. Measures of PTSD severity, depressive symptoms, alcohol and substance use, and self-compassion were collected at baseline and 18 weeks later.Results: MDMA-AT led to statistically significant improvements in both UCS and CS. Significant improvements were also observed across all six subscales of the Self-Compassion Scale, including self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification, most with large effect sizes. Changes in UCS and CS significantly and fully mediated the effects of MDMA-AT compared to placebo plus therapy in reducing PTSD severity and depressive symptoms. Findings were not significant for alcohol and substance use outcomes.Conclusions: These findings suggest that self-compassion may play a critical role in the therapeutic effects of MDMA-AT. Further research is needed to investigate the role of self-compassion in MDMA-AT to refine and develop more targeted, effective interventions for individuals with PTSD and co-occurring depression.

01 Oct 2025·TALANTA

Screening and validation of sponge materials assembled to a sampling device for enrichment and determination of amphetamine drugs in exhaled breath by HPLC-TQ-MS/MS

Article

Author: Yang, Xiangliang ; Xu, Fei ; Fan, Huajun ; Huang, Qingda ; Xu, Congfei ; Yang, Hai ; Zhou, Jiedan

Exhaled breath aerosol (EBA) analysis of the amphetamine drugs (AMPs) and ephedrine (EPH) has a great potential to monitor illicit drug abuse due to its simple, non-invasive, convenient, and easily accepted sampling. Nevertheless, the extremely low concentration of AMPs and EPH in EBA poses great challenges to instrumental analysis. In this study, a self-designed sampling device equipped with sponge-based material was developed and coupled to high-performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry (HPLC-TQ-MS/MS) for monitoring of the AMPs and EPH in EBA. Accordingly, the cellulose sponge with high adsorption performance and low expiratory resistance was screened out from multiple commercial sponges, optimized its configuration performance, and assembled to the sampling device, reaching the adsorption rates of 81.6 ± 2.2-98.9 ± 2.5 % for EPH and typical AMPs, including amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, and 3,4-methylenedioxymethamphetamine. The combination of HPLC-TQ-MS/MS and the device containing cellulose sponge showed excellent analytical performance, with linearity in the range of 30.0-20000.0 pg/filter (R ≥ 0.9901), low detection limit of 1.6-8.4 pg/filter, and the recoveries of 86.5-94.5 %. The device also exhibited good reusability and applicability for the simulated EBAs at different levels. Furthermore, the proposed method was successfully applied for determination of EPH in volunteers' EBAs, whose contents suggested a good correlation with that in saliva. Kinetic analysis provided insights into the adsorption mechanism, further validating reliability of the method. Overall, the simple, cheap, available, and reusable cellulose sponge assembled to sampling device was advantageous for enriching and monitoring of trace illicit drugs in human EBA.

01 Oct 2025·ADDICTIVE BEHAVIORS

Illicit drug use and associated health risk behaviors among sexual minority youth

Article

Author: Sciolla, Andres F ; Kelly, Deirdra ; Duong, Jeffrey

OBJECTIVE:

This study examined the links between lifetime illicit drug use (e.g., cocaine, hallucinogens, ecstasy, heroin) and proximal health risk behaviors among adolescents and investigated sexual identity as a moderator.

METHODS:

We analyzed data from the Center for Disease Control's 2021 Youth Risk Behavior Survey (N = 17,232), a biennial, cross-sectional survey of a nationally representative sample of youth enrolled in grades 9 through 12 in the United States. Bivariate tabulations of weighted data were used to estimate the prevalence of health risk behaviors among lifetime illicit drug users and sexual minority youth who identified as lesbian, gay, bisexual, questioning, or another sexual identity (LGBQ+). Structural equation modeling was used to examine their associations. Wald testing was employed to test for effect modification.

RESULTS:

Illicit drug use was associated with a broad range of health risk behaviors among adolescents (e.g., cigarette and marijuana use, drinking and driving, use of alcohol and drugs before sex, and having multiple sex partners). There was a significant interaction between lifetime illicit drug use and sexual identity such that LGBQ+ youth who have ever engaged in illicit drug use had the greatest odds of health risk behaviors.

CONCLUSIONS:

Adolescents with a history of ever using illicit drugs are likely to engage in a wide array of health risk behaviors. Screening and offering counseling on these health risk behaviors may play a crucial role in ensuring that the sequela of drug use among adolescents is minimized, especially for LGBQ+ youth.

426

News (Medical) associated with Methylenedioxymetamfetamine

13 Jun 2025

·ir.cybin.com

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

- Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder (“MDD”) with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) - - Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company’s commercialization and manufacturing capabilities - - Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin’s clinical-stage pipeline - TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. “It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,” said Doug Drysdale, Chief Executive Officer of Cybin. “With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.” Recent Corporate Highlights Continued to expand its strategic clinical site partnership (“SPA”) program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance. Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003. Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline. Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows:U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular (“IM”) injection, including CYB004. U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular (“IM”) injection, including CYB004. Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics Recent statements and hiring decisions by senior U.S. Health and Human Services (“HHS”) and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways. The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include: In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a “top priority” and promised an “expeditious and rapid review” of clinical data.1 Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws.2 Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to “embrace” compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD.3 President Trump’s new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy.4 Cybin’s Chief Executive Officer Doug Drysdale recently appeared on Fox News and is increasingly sought by media outlets as a trusted commentator.5 On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows: Panel Title: The Home Stretch: Pivotal Trials and Preparing for Launch Date and Time: Thursday, June 19, 2025, at 9:30 a.m. MDT (11:30 a.m. EDT) About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram. Sources Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company’s partnership with Osmind; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company’s annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations. Neither Cboe Canada, nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. Investor & Media: Gabriel Fahel Chief Legal Officer Cybin Inc. 1-866-292-4601 irteam@cybin.com – or – media@cybin.com

Phase 3Phase 2

03 Jun 2025

·www.sciencedaily.com

Clinical research on psychedelics gets a boost from new study

As psychedelics gain traction as potential treatments for mental health disorders, an international study stands to improve the rigor and reliability of clinical research. As psychedelics gain traction as potential treatments for mental health disorders, an international study led by researchers at McGill University, Imperial College London, and the University of Exeter stands to improve the rigour and reliability of clinical research. Up to now, psychedelic clinical trials have had what has been widely acknowledged as a critical flaw: the failure to properly account for how a person's mindset and surroundings influence the effects of psychedelics such as MDMA and psilocybin. This gap has led to inconsistent study results, making regulatory approval more difficult. To address this, the researchers conducted a Delphi consensus study, bringing together 89 experts from 17 countries for a multi-round debate. The result is the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, published in Nature Medicine, a 30-item checklist, representing the first global agreement on which psychosocial factors have the greatest impact on a psychedelic experience. "For decades, we've known that psychedelics don't work in isolation. The person's mindset, the therapy room, even the music playing all influence outcomes," said co-lead author Chloé Pronovost-Morgan, a researcher at McGill University and Imperial College London. "Two trials using the same psychedelic drug, at the same dose, can produce completely different results depending on the environment." This approach challenges the way psychoactive drugs are typically studied, where scientists try to control or eliminate outside variables to isolate a drug's effects. These guidelines recognize that context is crucial and should be studied directly. Why guidelines matter By offering a standard framework for evaluating and reporting these variables, the guidelines aim to make trial outcomes more consistent and comparable across studies. Leor Roseman from the University of Exeter is co-senior author and said: "Having clear guidelines for contextual considerations is essential to understand the effects of psychedelics and how they work differently from other psychiatric medications. Our guidelines will also help in replicating results and understanding the true therapeutic potential of psychedelics." The lack of standards has had consequences beyond the research lab, Pronovost-Morgan explained. The U.S. Food and Drug Administration recently rejected MDMA-assisted therapy for post-traumatic stress disorder, citing inconsistent reporting across trials as a key reason for the decision. "There is immense public interest in psychedelic therapies, particularly for individuals suffering from debilitating mental health conditions like PTSD, depression and anxiety, which have not responded to existing treatments," said co-senior author Kyle Greenway, Assistant Professor in McGill's Division of Social and Transcultural Psychiatry and a researcher at the Lady Davis Institute for Medical Research. "Our guidelines offer a new gold standard for psychedelic research, helping bring these treatments to those who need them most." The research team is organizing a three-day workshop in October, funded by McGill's Healthy Brains, Healthy Lives initiative, where leading experts in psychedelics and neuroscience will discuss how the guidelines can be integrated into research and clinical practice.

Clinical Study

30 May 2025

·www.globenewswire.com

PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla

TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), has become aware of unknown parties illegally retailing a nasal spray online, falsely claiming to be a PharmAla Biotech product and unlawfully using PharmAla logos and trademarks. PharmAla is issuing this warning in order to protect consumers and patients. PharmAla’s LaNeo MDMA drug products are exclusively available through a qualified practitioner’s prescription and Health Canada authorization and administered under the oversight of medical professionals. PharmAla does not, and will not, sell any products directly to consumers; PharmAla does not currently produce a nasal spray. The contents of any nasal spray purporting to be made by PharmAla are unknown and could be harmful to human health. PharmAla strongly urges any and all users who have purchased any unauthorized product to responsibly dispose of it immediately. PharmAla Biotech’s mission remains unchanged: to support individuals with legitimate medical needs with the supply of clinical grade LaNeo™ MDMA through legal and regulated channels. We will continue to advance this mission through our work with clinical trials and Health Canada's Special Access Program (SAP). Qualified medical practitioners seeking access for their patients through the SAP can submit applications directly to Health Canada. Practitioners are also encouraged to register through our dedicated portal at: https://sap.pharmala.ca/physician-portal-application/. For more details on Health Canada's Special Access Program for psychedelic-assisted psychotherapy, visit: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html. If you have questions about obtaining legitimate PharmAla products, the special access program, or wish to report suspicious products claiming association with our brand, please reach out to us directly for more information and assistance. About PharmAla PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. For more information, please contact:Nicholas KadyshChief Executive OfficerPharmAla Biotech Holdings Inc.Email: press@PharmAla.caPhone: 1-855-444-6362Website: www.PharmAla.ca Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “strategy”, “expects” or “does not expect”, “intends”, “continues”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “will be taken”, “will launch” or “will be launching”, “will include”, “will allow”, “will be made” “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding the use of proceeds from the Offering, the Company continuing to grow its revenue and the Company building on the success of this past year. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including but not limited to the risk factors discussed under the heading “Risk Factors” in the Company’s management’s discussion and analysis, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at www.sedarplus.ca, which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99fc7c88-8271-4615-81b5-20ab895c2507

100 Deals associated with Methylenedioxymetamfetamine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Methylenedioxymetamfetamine	-	DB01454

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stress Disorders, Post-Traumatic	NDA/BLA	United States	Lykos Therapeutics, Inc.	13 Dec 2023
Anorexia Nervosa	Phase 2	-	Lykos Therapeutics, Inc.	01 Feb 2026
Binge-Eating Disorder	Phase 2	-	Lykos Therapeutics, Inc.	01 Feb 2026
Alcoholism	Phase 2	-	Awakn Life Sciences, Inc.	05 May 2022
Anxiety Disorders	Phase 2	United States	Lykos Therapeutics, Inc.	14 May 2015
Autistic Disorder	Phase 2	United States	Lykos Therapeutics, Inc.	11 Apr 2014
Liver Injury	Phase 1	United States	Lykos Therapeutics, Inc.	29 Mar 2026
Hyperexplexia Hereditary	Phase 1	United States	Lykos Therapeutics, Inc.	14 Mar 2017
Mood Disorders	Phase 1	Switzerland	Universitätsspital Basel	01 Jun 2001
Substance-Related Disorders	Phase 1	Switzerland	Universitätsspital Basel	01 Jun 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04030169 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	21	Midomafetamine HCl	pmtcbmhdyt(nucwdmhbag) = chsxildhnl blbuyzenyq (ypkhogylwi, dcjffgkahf - sxiiafiwpi) View more	-	28 Jan 2025
NCT04714359 (MAPPUSX, CTgov)	Phase 3	Stress Disorders, Post-Traumatic	87	Midomafetamine HCl	qlxxmmhkyo(rqpdptjemy) = xvfcpdlkcb lqxhmifkmi (lssroznenj, dbtjsepesv - egnqeophhs) View more	-	29 Nov 2024
ESC2024	Not Applicable	-	-	Recreational drug users	rdyiafvpwo(ceuvdzhwnk) = ehwpworxiy tkgzjndyzr (tmgazbdmqu )	-	31 Aug 2024
ESC2024	Not Applicable	-	-	Non-users	rdyiafvpwo(ceuvdzhwnk) = hcbklelurv tkgzjndyzr (tmgazbdmqu )	-	31 Aug 2024
NCT03790618 (ESP, CTgov)	Phase 1	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Placebo)	ohnighxwoh(blifwekidx) = vgvycdktum rtcnqepnix (pzjzawthom, 3.22) View more	-	05 Jan 2024
NCT03790618 (ESP, CTgov)	Phase 1	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Low Dose MDMA)	ohnighxwoh(blifwekidx) = xhpjthhxeo rtcnqepnix (pzjzawthom, 3.14) View more	-	05 Jan 2024
NCT04077437 (MAPP2, CTgov)	Phase 3	Stress Disorders, Post-Traumatic	121	Therapy+Midomafetamine (Experimental: MDMA-assisted Psychotherapy)	jokqhoogmv(uwfrckwrnf) = ipzcguivrr fthpvnxyfc (yruhjkymry, rokvwhmsri - khsbwbczec) View more	-	11 Oct 2023
NCT04077437 (MAPP2, CTgov)	Phase 3	Stress Disorders, Post-Traumatic	121	Placebo (Placebo Comparator: Placebo)	djcafjnrhg(jubdkcfegv) = bjdtjduwnp enwskeztme (lzevuzzyns, qhoywmgyqi - cepioleaez)	-	11 Oct 2023
OR17-01 (ENDO2023)	Not Applicable	Diabetes Insipidus, Neurogenic oxytocin	30	MDMA (Ecstasy)	voqhdsebvt(vmzhfcljfh) = lmzspglrrt wuwdkpeixu (lbzysystje, 3 - 17) View more	Positive	05 Oct 2023
OR17-01 (ENDO2023)	Not Applicable	Diabetes Insipidus, Neurogenic oxytocin	30	Placebo	voqhdsebvt(vmzhfcljfh) = qcvedmwxew wuwdkpeixu (lbzysystje, 0 - 2) View more	Positive	05 Oct 2023
IEC2023	Not Applicable	EEG activity	-	MDMA (Non-substance users)	wenvwjymkg(yagbirmgjx) = volxxaahxb wjiagegdcj (eqynyfonlb, +/ - 1.5)	Negative	04 Sep 2023
NCT01458327 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	3	3,4-methylenedoxymethamphetamine (MDMA)	dssvmyzhho(evzitajaiu) = gpxpigjbme ndwpymjsyh (whojgdovxq, 1.53) View more	-	03 Nov 2021
NCT00090064 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	23	Lactose placebo pill	zgklhjdjij(xmmzuvkbxx) = ycikrqcbox rzcjqtnnry (xvzwxtmnwv, 20.47) View more	-	25 Oct 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis